With an Impact Factor of 3.831, Frontiers in Pharmacology is the 2nd most cited open-access journal in Pharmacology & Pharmacy

2018 update: Frontiers in Pharmacology continues to rank among the world’s top pharmacology journals in terms of influence and quality, as shown by our analysis of the 2017 Journal Citation Reports (JCR-2017; 2018, Clarivate Analytics), 2017 CiteScore edition (2018, Scopus, Elsevier) and other impact metrics.

► See full analysis

256 journals were listed in the category of Pharmacology & Pharmacy in the 2016 edition of the Journal Citation Reports (JCR), of which 20 were open-access (OA).

The Impact Factor (IF) is measured each year and reported in the JCR by Clarivate Analytics (formerly known as Thomson Reuters), along with citations and other metrics of journal impact. The IF of a journal is the average number of citations received last year to articles published in the previous two years – and is universally regarded as a metric of journal quality. The total number of citations captures how much research is built on the papers published in a journal and is therefore a measure of influence of a journal on a field. As such, the 2016-JCR analysis is based on citations in 2016 to articles published in 2014 and 2015. This analysis indicates that Frontiers in Pharmacology ranks among the top pharmacology journals in the world**.**

Scientific Excellence at Scale

Frontiers has become one of the largest open-access publishers in the world and is leading many of the technological innovations in Open Science. We engineered our Collaborative Peer Review with a review mandate focused on enhancing article quality by means of rigorous and constructive feedback from expert reviewers, quick and direct interactions between authors, reviewers and the editor. We enable their work with our unique review forum platform, and we introduced transparency and accountability by acknowledging reviewers and editors on the published articles.

With journals listed across 20 academic categories in the 2016-JCR, Frontiers journals rank in the top percentiles of Impact Factors and total citations. This confirms the rapidly growing success and influence of the Frontiers Open Science model, that consistently delivers scientific excellence at scale.

All of this is only possible with a stellar editorial board of researchers. Frontiers congratulates Field Chief Editor Théophile Godfraind and all Specialty Chief Editors, as well as the diligent work of the Associate and Review Editors and the Frontiers Journal Management team for this outstanding achievement.

Frontiers in Pharmacology Editorial Board

(see full  board here)

Théophile Godfraind, Frontiers Media SA | Field Chief Editor, Pharmacology

Martin Michel, Johannes Gutenberg University of Mainz | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology

Jeffrey Atkinson, Université de Lorraine | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology

Eliot Ohlstein, Drexel University | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology

Jaime Kapitulnik, The Hebrew University of Jerusalem | Specialty Chief Editor, Drug Metabolism and Transport

Michael Heinrich, University College London (UCL) | Specialty Chief Editor, Ethnopharmacology

Yung-Chi Cheng, Yale University | Specialty Chief Editor, Ethnopharmacology

Salvatore Salomone, University of Catania | Specialty Chief Editor, Experimental Pharmacology and Drug Discovery

Angelo Izzo, University of Naples Federico II | Specialty Chief Editor, Gastrointestinal and Hepatic Pharmacology

Paola Patrignani, University of Chieti-Pescara | Specialty Chief Editor, Inflammation Pharmacology

George Christ, University of Virginia | Specialty Chief Editor, Integrative and Regenerative Pharmacology

Alex Chen, University of Pittsburgh Medical Center | Specialty Chief Editor, Integrative and Regenerative Pharmacology

Nicholas Barnes, University of Birmingham | Specialty Chief Editor, Neuropharmacology

Anne Zajicek, National Institutes of Health | Specialty Chief Editor, Obstetric and Pediatric Pharmacology

Jeffrey Barrett, Children’s Hospital of Philadelphia | Specialty Chief Editor, Obstetric and Pediatric Pharmacology

Dominique Dubois, Free University of Brussels | Specialty Chief Editor, Pharmaceutical Medicine and Outcomes Research

Ulrich Zanger, Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie (IKP) | Specialty Chief Editor, Pharmacogenetics and Pharmacogenomics

Olivier Feron, Université Catholique de Louvain | Specialty Chief Editor, Pharmacology of Anti-Cancer Drugs

Philippe Lory, Centre national de la recherche scientifique (CNRS) | Specialty Chief Editor, Pharmacology of Ion Channels and Channelopathies

Diana Conte Camerino, University of Bari Aldo Moro | Specialty Chief Editor, Pharmacology of Ion Channels and Channelopathies

Ursula Gundert-Remy, Bundesinstitut für Risikobewertung | Specialty Chief Editor, Predictive Toxicology

Paolo Montuschi, Universita Cattolica del Sacro Cuore | Specialty Chief Editor, Respiratory Pharmacology

Alastair Stewart, University of Melbourne | Specialty Chief Editor, Translational Pharmacology